Dina Chaya

Imago BioSciences, Inc. operates as a clinical-stage biopharmaceutical company that develops novel anti-cancer therapeutics. It translates science of genetics and epigenetics enzymes into novel medicines for treating myeloid diseases that pose challenges to patients, families, and physicians. The company also translates insights into transformative therapies that alter the history of disease allowing patients to live longer and disease-free lives. Imago BioSciences was founded by Hugh Young Rienhoff, Jr., Laura G. Eichorn and Jennifer Peppe on March 29, 2012 and is headquartered in Redwood City, CA.

Attenua, Inc. engages in the provision of biopharmaceutical services. The company was founded by Jing Liang and is headquartered in San Mateo, CA.

Neomed Management (Jersey) Ltd. is an investment firm invests in innovative healthcare and life science companies. The company is headquartered in St. Helier, the United Kingdom.

Endosense SA operated as a medical technology company, which focused on reproducibility of catheter ablation for the treatment of cardiac arrhythmias. The firm's flagship product was TactiCath Quartz that helped physicians to measure contact force during the catheter ablation procedure. The company was founded by Vitali Verin, Giovanni Leo, and Nicolas Aeby in 2003 and was headquartered in Geneva, Switzerland.

IFM Quattro, Inc. is a biotechnology company. The company is headquartered in Boston, MA.

IFM Cinque, Inc. is a biotechnology company. The company is headquartered in Boston, MA.

IFM Continua, Inc. engages in the provision of biotechnology services. The company is headquartered in Boston, MA.

Invest Europe is a Belgian company that operates as a private equity, venture capital and infrastructure investment company. The company is based in Brussels, Belgium.

Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022.

The Monks Investment Trust Plc which focuses on portfolio of global quoted entities. It seeks for long-term holdings and capital growth, which takes priority over income and dividends. The company was founded in 1929 and is headquartered in Edinburgh, the United Kingdom.

OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London.